Cyclopharm said its flagship product, Technegas, has been awarded the maximum three-year transitional pass-through reimbursement status by the Center for Medicare and Medicaid Services.
The status, commencing on July 1, allows Technegas to be reimbursed separately from the procedures in which it is used.
The significance of transitional pass-through status includes better financial incentives for healthcare providers, expedited market access, improved patient access, and a competitive advantage for hospitals adopting new technologies.